Merck Frosst Canada & Co.

Merck Frosst Canada, Inc.

Helene Perrier

Yves Girard

Zhaoyin Wang

Daniel Dube

Pierre A Hamel

Petpiboon Prasit

Richard W Friesen

Richard Frenette

Michel Gallant

Patrick Lacombe

Denis Deschenes

Mario Girard

Dwight MacDonald

Anthony Mastracchio

Cedrickx Godbout

Daaniel Guay

Ian Street

Novel substituted 8-arylquinolines, wherein the aryl group at the 8-position contains a substituent substituted-alkenyl group, are PDE4 inhibitors.

Substituted 8-arylquinoline phosphodiesterase-4 inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3&prime;,5&prime;-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE 4).

Heterosubstituted pyridine derivatives as PDE 4 inhibitors

Compounds having the formula I: ##STR1## are inhibitors of the PLA.sub.2 s enzymes. These compounds are useful as anti-allergic, anti-asthmatic, they are also useful in treating various inflammatory diseases such as rheumatoid arthritis, osteoarthritis, bursitis, psoriasis; immunoinflammatory disorders such as contact dermatitis, irritable bowel disease and the like.

Bis(aryloxy)alkanes as inhibitors of phospholipase A.sub.2 enzymes

Growing community of inventors

Montreal, Canada

Helene Perrier